| Revenue growth | 18.89% YoY for FY26; targeting ~60% growth for FY27. |
|---|---|
| Margins | Targeting 15% EBITDA in FY27, scaling to 20% by FY28. |
| Demand visibility | Increasing digital engagement; 1.5 lakh Instagram followers and growing patient inflow. |
| Management confidence | High; confident in 18-20% healthy growth and scaling to 30%. |
Growth
FY26 Revenue grew 18.89% to ₹106.91cr. PAT increased to ₹8.99cr. H2 FY26 PAT grew 22.77% YoY to ₹4.15cr.
Outlook
Targeting FY27 revenue of ₹170-180cr. Medium-term FY28 target of ₹250-300cr with 20% EBITDA margins and 300 hospital beds.
Risks
High marketing spend (₹40-45cr targeted), operational challenges in non-medical franchise models, and potential dilution from preferential warrants.
Earnings Call filed with NSE, NSE: MADHAVBAUG. Summary written with AI assistance from the document.
Vaidya Sane Ayurved Laboratories Ltd: key numbers
- Share price
- ₹172.80
- Market cap
- ₹181.7 Cr
- Revenue (annual)
- ₹106.9 Cr
- Net profit (annual)
- ₹8.99 Cr
- P/E (TTM)
- 20.2×Sector 34.2×
- Promoter holding
- 66.34%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vaidya Sane Ayurved Laboratories Ltd
All →Vaidya Sane Ayurved Laboratories Annual General Meeting
Vaidya Sane Ayurved Laboratories will hold its 27th Annual General Meeting on September 30, 2026, via video conferencing. The company also filed its FY 2025-26 Annual Report.
Vaidya Sane Ayurved Laboratories Board Meeting Outcome
The company's board approved the 27th AGM details, director/auditor re-appointments, an increase in MD remuneration, and the introduction of the 'VSALL - ESOP 2026' scheme.
Vaidya Sane Ayurved Laboratories Other Announcement
Vaidya Sane Ayurved Laboratories filed a statement of deviation or variation in fund utilization pursuant to Regulation 32(1) for the quarter ended June 30, 2026.
Vaidya Sane Ayurved Laboratories Management Change
Vaidya Sane Ayurved Laboratories announced the resignation of Rohit Madhav Sane as CEO. Mr. D. Ramakrishna has been appointed as the new CEO and KMP.
Vaidya Sane Ayurved Laboratories Results Correction
The company clarified its earlier financial results submission to the NSE, addressing the missing balancing figure note and rectifying discrepancies in its Consolidated XBRL filing.
Vaidya Sane Ayurved Laboratories Business Update
Vaidya Sane Ayurved Laboratories Ltd received Indian Patent No. 593487 for a herbal formulation method. The grant enhances its IP portfolio and supports its long‑term strategy.